Collectively, these studies demonstrate that high SLFN11 expression is a promising biomarker for sensitivity to PARP inhibitor activity in SCLC, but prospective validation is needed and integration of multiple markers may improve predictive ability. This evidence concerns the gene SLFN11 and small cell lung carcinoma.